Logo
x

Search

Subscribe Now

remegen

Remegen Reports P-III Trial Data of Telitacicept for Generalized Myasthenia Gravis (gMG)

Remegen Reports P-III Trial Data of Telitacicept for Generalized Myasthenia Gravis (gMG)

  • April 9, 2025
RemeGen Reports the First Patient Enrollment in the P-III Study of Telitacicept to Treat Myasthenia Gravis

RemeGen Reports the First Patient Enrollment in the P-III Study of Telitacicept to Treat Myasthenia Gravis

  • August 6, 2024
The US FDA Grants Fast Track Designation to RemeGen's RC88 for Ovarian Cancer

The US FDA Grants Fast Track Designation to RemeGen's RC88 for Ovarian Cancer

  • January 12, 2024
RemeGen Reports the Result of Disitamab Vedotin (RC48) in the P-II trial for the Treatment of Urothelial Carcinoma

RemeGen Reports the Result of Disitamab Vedotin (RC48) in the P-II trial for the Treatment of Urothelial Carcinoma

  • November 28, 2023
RemeGen Published P-II Clinical Study Results of Telitacicept for Primary Sjogren's Syndrome in Rheumatology Journal

RemeGen Published P-II Clinical Study Results of Telitacicept for Primary Sjogren's Syndrome in Rheumatology Journal

  • July 25, 2023
RemeGen Entered into a Clinical Research Agreement with Innovent to Evaluate RC88 and RC108 Combined with Tyvyt (sintilimab) for Advanced Solid Tumors

RemeGen Entered into a Clinical Research Agreement with Innovent to Evaluate RC88 and RC108 Combined with Tyvyt (sintilimab) for A...

  • July 10, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.